IP Library Patent Application 14453937
Patent Application
App. No. 14/453,937

STEM CELL BASED ANTI-CANCER COMPOSITIONS AND METHODS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/453,937
Abstract

The present invention provides compositions and methods for target radiotherapeutic treatment of cancer. Freshly isolated or culture expanded ELA stem cells are loaded with at least one of a diagnostic agent and a therapeutic agent, and the stem cells are then introduced into a subject. The loaded ELA stem cells migrate to location of cancer and form the basis both of diagnostic imaging and of directed Neutron Capture Therapy. Treatment of a subject may include ELA stem cell-based NCT radiotherapy as an adjunct to traditional therapies. An ELA stem cell-based diagnostic preparation can be used directly, or as a further addition to current imaging agents and methods.

Claims (19)

1 . A cell-based preparation comprising: a population of loaded ELA stem cells further comprising a diagnostic agent and a therapeutic agent.

2 . The cell-based preparation of claim 1 , wherein the diagnostic agent is Gadolinium-157.

3 . The cell-based preparation of claim 1 , wherein the therapeutic agent is selected from at least one of Gadolinium-157 and Boron-10.

4 . The cell-based preparation of claim 1 , wherein the loaded ELA stem cells are in an amount of 10 2 to 10 8 .

5 . The cell-based preparation of claim 4 , wherein the loaded ELA stem cells are in a volume of 0.5 to 10 ml.

6 . The cell-based preparation of claim 4 , further comprising a pharmaceutically acceptable solution.

7 . The cell-based preparation of claim 1 , further comprising a perfluorate agent.

8 . The cell-based preparation of claim 4 , further comprising unloaded ELA stem cells, wherein the ratio of the loaded cells to the unloaded cells is greater than 2:1.

9 . The cell-based preparation of claim 8 , wherein the ratio of the loaded cells to the unloaded cells is greater than 5:1.

10 . A method of treating a subject having a cancer or a neoplasm, the method comprising:

introducing to the subject a quantity of the cell-based preparation of claim 1 or claim 4 which targets to the neoplasm, and

administering radiotherapy by exposing the subject to a neutron source of greater than 0.5 eV to about 10 keV, thereby treating the neoplasm of the subject by the radiotherapy.

11 . The method according to claim 10 , further comprising prior to exposing, imaging the subject.

12 . The method of claim 10 , further comprising prior to introducing, obtaining from the subject a population of ELA cells, isolating the ELA cells and extending the ELA cells by culture prior to loading and administration to the subject.

13 . A patient-specific master cell bank prepared by the method of claim 12 prior to introducing to the subject the cell-based preparation.

14 . A kit comprising: a single dose cell-based preparation of loaded ELA stem cells of claim 1 , appropriate sterile packaging, and instructions for use.

15 . A method of manufacture for a cell-based preparation comprising: obtaining a population of ELA stem cells, and culturing the cells under conditions suitable to permit uptake by the cells of a diagnostic agent and a therapeutic agent.

16 . The method of claim 15 , wherein the diagnostic and therapeutic agents is selected from at least one of Gadolinium-157 and Boron-10.

17 . A cell bank of ELA cell lines each specific to a patient, wherein populations of the ELA cells are obtained from the patient, and are isolated and are expanded by culture to obtain a patient-specific ELA cell bank.

Assignments (1)
CHANGE OF NAME Recorded Nov 11, 2015
From: PARCELL LABORATORIES
To: ASCLEPIUS LABORATORIES, INC.
Reel/Frame 037088/0989 →